BUSINESS
Followup Data Backs Padcev-Keytruda Combo for 1st Line Bladder Cancer: Astellas/Seattle Genetics
Astellas Pharma/Seattle Genetics’ antibody-drug conjugate (ADC) Padcev (enfortumab vedotin) continued to demonstrate manageable safety profiles, along with encouraging clinical activities in a PIb/II study in combination with the anti-PD-1 antibody Keytruda (pembrolizumab), according to updated results of the study published…
To read the full story
Related Article
BUSINESS
- Shionogi Closes US$2 Billion IntraBio Buyout, Gains Rare Disease Drug
November 19, 2026
- AbbVie Japan Launches Skyrizi 55 mg for Pediatric Psoriasis
November 19, 2026
- Japan Drug Makers’ H1 Sales Surge 14.7% as Weak Yen Fuels Growth
November 18, 2026
- Towa, Sawai Grow Sales on Supply Gains; Biosimilars Emerge as New Focus for Others
November 18, 2026
- Kyowa Kirin to Drop Onglyza in First for Originator DPP-4 Inhibitors
November 18, 2026
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…





